The FDA granted a restricted approval for GSK’s antibody‑drug conjugate Blenrep, clearing it for use in combination with Velcade for patients whose multiple myeloma returned or progressed after at least two prior lines of therapy, while rejecting its use paired with Pomalyst. The agency’s decision follows mixed trial results and safety concerns raised in prior confirmatory studies. GSK emphasized trial data—DREAMM‑7 in particular—that supported benefit in the approved regimen, while regulators and advisers expressed reservations about dosing and ocular toxicity in other combinations. The ruling highlights a case‑by‑case FDA approach to complex oncology agents with prior safety and efficacy controversies.